exploring medi0680/durvalumab versus nivolumab in metastatic ccrcc
Published 4 years ago • 180 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
1:32
dr. voss on phase i/ii trial data of medi0680/durvalumab versus nivolumab in mrcc
-
4:10
combination of medi0680, an anti-pd-1 antibody, with durvalumab, an anti-pd-l1 antibody
-
1:22
discussing the phase ii study of lenvatinib/pembrolizumab in metastatic ccrcc
-
4:39
nivolumab and ipilimumab for metastatic kidney cancer
-
1:55
investigating responses to nivolumab and ipilimumab in advanced rcc
-
1:25
dr. motzer discusses nivolumab for mrcc
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
1:42
dr. mcdermott on immotion150 trial in rcc
-
1:43
dr. sonpavde discusses a study of fixed-dose durvalumab and tremelimumab in urothelial carcinoma
-
6:37
cabozantinib in combination with nivolumab demonstrated continued survival and hrqol in arcc pat...
-
3:46
nivoren: nivolumab in a 'real world setting' for metastatic clear-cell renal cell carcinoma
-
4:15
case review: symptomatic metastatic renal cell cancer
-
5:23
immunotherapy-based management of metastatic clear-cell and variant rcc: what can we achieve?
-
3:47
other clinical trials in renal cell carcinoma
-
4:16
recent advances in metastatic kidney cancer
-
3:45
combination immunotherapy in newly diagnosed mrcc
-
1:33
checkmate 920: nivolumab plus ipilimumab for renal cell cancer
-
4:43
nivolumab in renal cell carcinoma